Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Astrazeneca Plc ADR (NQ: AZN )

77.04 +0.07 (+0.09%)
Official Closing Price Updated: 4:15 PM EDT, May 16, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 2,941,779
Open 76.72
Bid (Size) 76.97 (2)
Ask (Size) 78.00 (1)
Prev. Close 76.97
Today's Range 76.58 - 77.22
52wk Range 60.47 - 77.94
Shares Outstanding N/A
Dividend Yield 1.21%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
AstraZeneca's COVID-19 Prevention Therapy Cuts Risk Of Infection In Patients With Weaker Immunity, Data Shows
AstraZeneca's Phase 3 SUPERNOVA trial shows sipavibart significantly reduces symptomatic COVID-19 in immunocompromised patients. The trial met primary endpoints, showing effectiveness against various... 
Via Benzinga
Exposures COVID-19
Pfizer, AstraZeneca, Sanofi And Mainz Biomed To Uplevel Europe's Pharma Game
On Sunday, Pfizer (NYSE: PFE) and AstraZeneca Plc (NASDAQ: AZN) were among the pharmaceutical companies who announced they will be investing a total of nearly $1 billion in their operations in France,... 
Via Benzinga

Performance

YTD
+12.63%
+12.63%
1 Month
+12.85%
+12.85%
3 Month
+22.60%
+22.60%
6 Month
+20.75%
+20.75%
1 Year
+3.24%
+3.24%

More News

Read More
7 Pharma Stocks Harnessing AI Brainpower for Big Breakthroughs
Via InvestorPlace
Topics Artificial Intelligence
Exposures Artificial Intelligence
7 Blue-Chip Stocks to Protect Your Wealth as the Economy Slows
Via InvestorPlace
Topics Economy
Exposures Economy
Healthcare Giants Pfizer, AstraZeneca, Sanofi Inject Over $2B To Boost France's Healthcare Sector
Via Benzinga
Forget Johnson & Johnson: Buy This Better Healthcare Stock Instead
Via The Motley Fool
Catalyst's New CEO Has Big Ideas For The Small Biotech
Via Investor's Business Daily
3 Biotech Stocks to Sell in May Before They Crash & Burn
Via InvestorPlace
7 Weight Loss Drug Stocks Poised for Explosive Growth by 2025
Via InvestorPlace
Top 5 Health Care Stocks That Could Sink Your Portfolio In Q2
Via Benzinga
Elon Musk Breaks Ranks With GOP By Praising Genetic Engineering Tech That Helped Fight COVID-19: 'Digital Medicine With Incredible Potential'
Via Benzinga
Mitigating Muscle Loss Becoming More Vital, Global Cancer Cachexia Market Projected to Reach $3.3 Billion in 2024
Via FinancialNewsMedia
Mitigating Muscle Loss Becoming More Vital, Global Cancer Cachexia Market Projected to Reach $3.3 Billion in 2024
From FN Media Group LLC
Via GlobeNewswire
AstraZeneca Pulls Plug On Vaxzevria COVID-19 Vaccine Amid Surplus of Updated Vaccines
Via Benzinga
Exposures COVID-19
7 Stocks to Buy Before the Next ‘Great Reset’ Begins in 2024
Via InvestorPlace
Actinium Pharmaceuticals (NYSE: ATNM): A Prime Target in a Wave of Radiopharmaceutical Mergers and Acquisitions
Via AB Newswire
Cellectis Announces Completion of the Additional Equity Investment by AstraZeneca
From Cellectis Inc.
Via GlobeNewswire
Top Analyst Reports For AstraZeneca, Qualcomm & FedEx
Via Talk Markets
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
CALQUENCE combination regimen demonstrated statistically significant and clinically meaningful improvement in progression-free survival in 1st-line mantle cell lymphoma in ECHO Phase III trial
From AstraZeneca
Via Business Wire
Federal Trade Commission Targets 'Junk Patent Listings' For Diabetes, Weight Loss, Asthma Drugs From Companies Like Novo Nordisk, AstraZeneca
Via Benzinga
Topics Intellectual Property
Exposures Intellectual Property
AstraZeneca unveils latest research across key respiratory and immune-mediated diseases at ATS 2024 showcasing strength of its broad pipeline and portfolio
From AstraZeneca
Via Business Wire
AstraZeneca Admits Its COVID-19 Vaccine May Cause Blood Clotting Side Effect In Very Rare Case, But Causal Mechanism Unknown
Via Benzinga
Topics Lawsuit
Exposures COVID-19 Financial Legal
Double Good News For AstraZeneca's Breast Cancer Drugs
Via Benzinga
ENHERTU® (fam-trastuzumab deruxtecan-nxki) improved PFS in HER2-low and ultralow
From AstraZeneca
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.